Final Evidence Report and Meeting Summary
CTAF

PDF cover

CAR-T Therapies: Final Evidence Report

ICER’s final report on the comparative clinical effectiveness and value of tisagenlecleucel (KymriahTM, Novartis) and axicabtagene ciloleucel (YescartaTM, Kite Pharma/Gilead), including key policy recommendations.

View

View All Materials on this Topic or Go Back to View More Materials